1. Scrip
  2. >>Business
  3. >>Strategy

Dermavant’s Vtama Appears Well Positioned To Compete With Other Topicals In AD

 
• By Joseph Haas

Approved for psoriasis, Vtama met the primary and secondary endpoints in first of two Phase III atopic dermatitis studies. The Roivant affiliate will position the drug as a two-in-one solution for both.

Topical dermatology
Dermavant is working toward adding atopic dermatitis to Vtama's label • Source: Shutterstock

Roivant Sciences Ltd. affiliate Dermavant Sciences Inc. said it hopes to offer its Vtama (tapinarof 1%) to physicians as a convenient, once-daily medication for two of the largest dermatology indications – psoriasis and atopic dermatitis (AD) – following a successful readout in the first two Phase III studies of the topical cream. Analysts hailed the data as offering a potential best-in-class profile for an AD topical, positioning it to compete with Incyte Corporation’s Opzelura (ruxolitinib) and Pfizer Inc.’s Eucrisa (crisaborole) as well as steroidal therapies.

Dermavant execs said during a 15 March investor call that the drug’s efficacy, safety and tolerability profile should open up a significant market opportunity in AD for Vtama, a first-in-class aryl hydrocarbon receptor agonist which obtained US Food and Drug Administration in May 2022 for topical treatment of plaque psoriasis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

How Much Does Biopharma Contributes To The US Economy?

 
• By Jessica Merrill

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

More from Business

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.